Peptide Report
Source-backed explainers, regulatory tracking, and research notes for readers trying to make sense of the peptide conversation.
BPC-157
Regulatory Watch
BPC-157 is widely discussed online in injury recovery and performance communities, but the public evidence and regulatory posture require careful separation from social-media claims.
Popular YouTube shows can flag what readers are hearing. We track them as media signals, then verify claims against primary sources before updating guides.
Retatrutide
Long-form doctor-led retatrutide discussion with monitoring, diet, exercise, and supplement chapters that may shape reader search behavior.
13K views · 57 comments · 54K subscribers · checked Jun 30, 2026
Track as a media signal; do not convert the episode into treatment, dosing, or purchasing guidance.
Retatrutide
High-view retatrutide explainer using strong outcome language; useful for identifying claims that need careful source separation.
615K views · 1.2K comments · 224K subscribers · checked Jun 30, 2026
Check claims against primary regulatory and trial sources before any page update.
Peptide science and safety
Large-audience peptide safety conversation that can influence mainstream questions and category-level search demand.
416K views · 1K comments · 7.6M subscribers · checked Jun 30, 2026
Use only to identify questions and themes; cite primary sources for factual claims.
Retatrutide
Another long-form retatrutide masterclass format that helps compare recurring claims and audience questions.
200K views · 665 comments · 390K subscribers · checked Jun 30, 2026
Treat as a discovery source for public questions, not as evidence.
Starting points for source-backed peptide research. These are editorial guide queues, not purchasing recommendations.
A ranked starting point for the pages most likely to need regulatory or source updates.
See guideThe peptide guides currently anchored by FDA advisory and risk-source records.
See guidePlain-English explainers that separate online claims from reviewed sources.
See guideHow the site keeps claims, citations, analytics, and review dates in one loop.
See guide
5-Amino-1MQ
Regulatory Watch
5-Amino-1MQ (5-amino-1-methylquinoline) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular metabolism and energy homeostasis. It has been promoted in biohacking and fitness communities as 'exercise in a pill' based on preclinical studies showing reversal of diet-induced obesity in mice. There are no published human clinical trials. The compound is not FDA-approved for any indication and is sold only as a research chemical.
AOD-9604
Regulatory Watch
AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment of human growth hormone (hGH) residues 177-191, developed by Metabolic Pharmaceuticals (Australia) as a lipolytic (fat-reducing) agent. Preclinical studies showed that this fragment retained the fat-reducing properties of hGH without its growth-promoting or diabetogenic effects. AOD-9604 advanced to Phase 2 clinical trials for obesity, but the trials failed to meet primary weight loss endpoints, and clinical development was discontinued. The peptide is not FDA-approved or TGA-approved for any indication and is sold as a research-use-only chemical. Despite the failed clinical program, AOD-9604 remains popular in the biohacking and fitness communities as a fat-loss agent.
Argireline (Acetyl Hexapeptide-8)
Evidence Guide
Argireline (Acetyl Hexapeptide-8, formerly Acetyl Hexapeptide-3) is a synthetic hexapeptide fragment of SNAP-25, a protein involved in neurotransmitter release and one of the targets of botulinum toxin. Marketed as a topical 'Botox alternative,' it is proposed to inhibit SNARE complex formation and reduce wrinkle depth. It is classified as an OTC cosmetic ingredient in the US and is widely used in anti-aging skincare formulations.
Cerebrolysin
Regulatory Watch
Cerebrolysin is a porcine brain-derived peptide preparation (neuropeptide concentrate) with proposed neurotrophic and neuroprotective activity. It is approved and marketed in over 40 countries for neurological indications including stroke and dementia, but is NOT approved by the FDA for use in the United States. Over 100 clinical trials have been conducted, primarily outside the US. Cochrane systematic reviews have examined its use in vascular dementia with mixed conclusions.
Browse the current peptide explainers by topic, status, and review depth.
5-Amino-1MQ
Regulatory Watch
5-Amino-1MQ (5-amino-1-methylquinoline) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular metabolism and energy homeostasis. It has been promoted in biohacking and fitness communities as 'exercise in a pill' based on preclinical studies showing reversal of diet-induced obesity in mice. There are no published human clinical trials. The compound is not FDA-approved for any indication and is sold only as a research chemical.
AOD-9604
Regulatory Watch
AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment of human growth hormone (hGH) residues 177-191, developed by Metabolic Pharmaceuticals (Australia) as a lipolytic (fat-reducing) agent. Preclinical studies showed that this fragment retained the fat-reducing properties of hGH without its growth-promoting or diabetogenic effects. AOD-9604 advanced to Phase 2 clinical trials for obesity, but the trials failed to meet primary weight loss endpoints, and clinical development was discontinued. The peptide is not FDA-approved or TGA-approved for any indication and is sold as a research-use-only chemical. Despite the failed clinical program, AOD-9604 remains popular in the biohacking and fitness communities as a fat-loss agent.
Argireline (Acetyl Hexapeptide-8)
Evidence Guide
Argireline (Acetyl Hexapeptide-8, formerly Acetyl Hexapeptide-3) is a synthetic hexapeptide fragment of SNAP-25, a protein involved in neurotransmitter release and one of the targets of botulinum toxin. Marketed as a topical 'Botox alternative,' it is proposed to inhibit SNARE complex formation and reduce wrinkle depth. It is classified as an OTC cosmetic ingredient in the US and is widely used in anti-aging skincare formulations.
Cerebrolysin
Regulatory Watch
Cerebrolysin is a porcine brain-derived peptide preparation (neuropeptide concentrate) with proposed neurotrophic and neuroprotective activity. It is approved and marketed in over 40 countries for neurological indications including stroke and dementia, but is NOT approved by the FDA for use in the United States. Over 100 clinical trials have been conducted, primarily outside the US. Cochrane systematic reviews have examined its use in vascular dementia with mixed conclusions.
CJC-1295
Evidence Guide
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog developed by ConjuChem with drug affinity complex (DAC) technology for extended half-life. It is not FDA-approved for any indication; ConjuChem discontinued clinical development. It is widely used in research-chemical and telehealth contexts, frequently stacked with ipamorelin.
Dihexa
Regulatory Watch
Dihexa (N-hexanoic-tyr-ile-(6) aminohexanoic amide) is a metabolically stabilized analog of angiotensin IV developed by researchers at Washington State University, including Joseph W. Harding and Jay W. Wright. It was designed to activate the hepatocyte growth factor (HGF)/c-Met receptor system, which is implicated in synaptogenesis and cognitive function. Dihexa has been studied only in animal models (rats and mice); no human clinical trials have been published. It is not FDA-approved for any indication and is sold as a 'research chemical' or supplement despite lacking any clinical safety or efficacy data in humans.
Latest Guides
| Topic | Status | Claims | Sources | Next review |
|---|---|---|---|---|
| 5-Amino-1MQ | Regulatory watch | 3 | 2 | 2026-07-29 |
| AOD-9604 | Regulatory watch | 3 | 3 | 2026-07-29 |
| Argireline (Acetyl Hexapeptide-8) | Evidence review | 3 | 3 | 2026-07-29 |
| BPC-157 | Regulatory watch | 2 | 3 | 2026-07-24 |
| Cerebrolysin | Regulatory watch | 3 | 4 | 2026-07-29 |
| CJC-1295 | Evidence review | 3 | 3 | 2026-07-29 |
| Dihexa | Research watch — preclinical only | 3 | 5 | 2026-07-29 |
| DSIP | Regulatory watch | 1 | 2 | 2026-07-24 |
| Epitalon | Regulatory watch | 1 | 2 | 2026-07-24 |
| Fisetin | Evidence review | 3 | 3 | 2026-07-29 |
| GHK-Cu | Evidence review | 1 | 1 | 2026-07-30 |
| Ipamorelin | Evidence review | 3 | 3 | 2026-07-29 |
| KPV | Regulatory watch | 1 | 2 | 2026-07-24 |
| LL-37 | Regulatory watch | 3 | 4 | 2026-07-29 |
| Matrixyl (Palmitoyl Pentapeptide-4) | Evidence review | 3 | 4 | 2026-07-29 |
| Metformin | Evidence review | 4 | 6 | 2026-07-29 |
| Methylene Blue | Regulatory watch | 3 | 4 | 2026-07-29 |
| MK-677 (Ibutamoren) | Evidence review | 3 | 4 | 2026-07-29 |
| MOTS-c | Regulatory watch | 1 | 2 | 2026-07-24 |
| NAD+ / NMN / NR | Regulatory watch | 4 | 8 | 2026-07-29 |
| Noopept | Research watch — registered in Russia, sold as supplement in US | 3 | 5 | 2026-07-29 |
| Rapamycin (Sirolimus) | Evidence review | 4 | 8 | 2026-07-29 |
| Retatrutide | Regulatory watch | 4 | 6 | 2026-07-29 |
| Selank | Research watch — preclinical and limited Russian clinical use | 3 | 3 | 2026-07-29 |
| Semaglutide | Evidence review | 4 | 11 | 2026-07-29 |
| Semax | Regulatory watch | 1 | 2 | 2026-07-24 |
| Sermorelin | Evidence review | 3 | 3 | 2026-07-29 |
| Spermidine | Evidence review | 3 | 5 | 2026-07-29 |
| TB-500 | Regulatory watch | 2 | 2 | 2026-07-24 |
| Tesamorelin | Regulatory watch | 3 | 4 | 2026-07-29 |
| Thymosin Alpha-1 | Regulatory watch | 3 | 3 | 2026-07-29 |
| Tirzepatide | Evidence review | 4 | 9 | 2026-07-29 |